Bicara Therapeutics (NASDAQ:BCAX) Announces Earnings Results, Misses Estimates By $0.08 EPS

Bicara Therapeutics (NASDAQ:BCAX) issued its quarterly earnings data on Thursday. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08), Zacks reports.

Bicara Therapeutics Stock Up 0.6 %

NASDAQ:BCAX traded up $0.08 during mid-day trading on Friday, hitting $13.48. The stock had a trading volume of 55,695 shares, compared to its average volume of 457,279. The stock’s 50 day moving average is $13.01. Bicara Therapeutics has a 52 week low of $11.10 and a 52 week high of $28.09.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. HC Wainwright raised their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a report on Thursday, March 13th. Finally, Wedbush reissued an “outperform” rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a report on Thursday. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Bicara Therapeutics currently has a consensus rating of “Buy” and an average target price of $36.50.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.